|
SEC24B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.27890000051801E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.78586999999286E-05 |
| Normal-vs-Stage2 |
6.151200E-04 |
| Normal-vs-Stage3 |
2.75130000004786E-06 |
| Normal-vs-Stage4 |
2.17679999999776E-05 |
| Stage1-vs-Stage2 |
8.146000E-01 |
| Stage1-vs-Stage3 |
3.633200E-01 |
| Stage1-vs-Stage4 |
3.963200E-01 |
| Stage2-vs-Stage3 |
6.938400E-01 |
| Stage2-vs-Stage4 |
6.337200E-01 |
| Stage3-vs-Stage4 |
8.864600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.1193999999447E-06 |
| Normal-vs-AfricanAmerican |
4.880000E-02 |
| Normal-vs-Asian |
7.78380000000523E-05 |
| Caucasian-vs-AfricanAmerican |
3.119200E-01 |
| Caucasian-vs-Asian |
6.090000E-01 |
| AfricanAmerican-vs-Asian |
2.189800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.14710000004492E-06 |
| Normal-vs-Female |
2.20829999997285E-06 |
| Male-vs-Female |
8.275000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.040640E-04 |
| Normal-vs-Age(41-60Yrs) |
3.07070000005183E-06 |
| Normal-vs-Age(61-80Yrs) |
1.10480000004021E-06 |
| Normal-vs-Age(81-100Yrs) |
2.485900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.904400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.031800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.507800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.773000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.560800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.276000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.599400E-01 |
| Classical-VS-Follicular |
9.863300E-03 |
| Classical-VS-Other |
3.911200E-01 |
| Classical-VS-Normal |
1.002950E-04 |
| Tall-VS-Follicular |
6.100600E-01 |
| Tall-VS-Other |
7.704600E-01 |
| Tall-VS-Normal |
3.810800E-04 |
| Follicular-VS-Other |
9.868800E-01 |
| Follicular-VS-Normal |
1.07000000004742E-06 |
| Other-VS-Normal |
2.358400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.59389999993587E-07 |
| Normal-vs-N1 |
1.5367799999999E-05 |
| N0-vs-N1 |
4.847600E-01 |
|
|
